Cited by 429Diabetes Treatment and ManagementPancreatic function and diabetesDiabetes Management and Research

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Open access

Degn, Kristine B., Juhl, Claus B., Sturis, Jeppe, Jakobsen, Grethe, Brock, Birgitte, Chandramouli, Visvanathan, Rungby, Joergen, Landau, Bernard R., Schmitz, Ole·2004·Diabetes

DOI 10.2337/diabetes.53.5.1187

Open this paper in CoChat — free account Open PDF

Abstract

Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for treating type 2 diabetes. We explored the effect of short-term (1 week) treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics in glycemia and circulating free fatty acids, islet cell hormone profiles, and gastric emptying during meals using acetaminophen. Furthermore, fasting endogenous glucose release and gluconeogenesis (3-3H-glucose infusion and 2H2O ingestion, respectively) were determined, and aspects of pancreatic islet cell function were elucidated on the subsequent day using homeostasis model assessment and first- and second-phase insulin response during a hyperglycemic clamp (plasma glucose ∼16 mmol/l), and, finally, on top of hyperglycemia, an arginine stimulation test was performed. For accomplishing this, 13 patients with type 2 diabetes were examined in a double-blind, placebo-controlled crossover design. Liraglutide (6 μg/kg) was administered subcutaneously once daily. Liraglutide significantly reduced the 24-h area under the curve for glucose (P = 0.01) and glucagon (P = 0.04), whereas the area under the curve for circulating free fatty acids was unaltered. Twenty-four-hour insulin secretion rates as assessed by deconvolution of serum C-peptide concentrations were unchanged, indicating a relative increase. Gastric emptying was not influenced at the dose of liraglutide used. Fasting endogenous glucose release was decreased (P = 0.04) as a result of a reduced glycogenolysis (P = 0.01), whereas gluconeogenesis was unaltered. First-phase insulin response and the insulin response to an arginine stimulation test with the presence of hyperglycemia were markedly increased (P < 0.001), whereas the proinsulin/insulin ratio fell (P = 0.001). The disposition index (peak insulin concentration after intravenous bolus of glucose multiplied by insulin sensitivity as assessed by homeostasis model assessment) almost doubled during liraglutide treatment (P < 0.01). Both during hyperglycemia per se and after arginine exposure, the glucagon responses were reduced during liraglutide administration (P < 0.01 and P = 0.01). Thus, 1 week’s treatment with a single daily dose of the GLP-1 derivative liraglutide, operating through several different mechanisms including an ameliorated pancreatic islet cell function in individuals with type 2 diabetes, improves glycemic control throughout 24 h of daily living, i.e., prandial and nocturnal periods. This study further emphasizes GLP-1 and its derivatives as a promising novel concept for treatment of type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/diabetes.53.5.1187

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Nowy rok, stare problemy, ale i nowe możliwości
Czupryniak, L. (2014) · Via Medica Journals · Cited by 1,192
Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 887
Self-citation
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 885
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M.-B., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diabetes.44.9.1126 · Cited by 878

Show all 50 references

Sorted by citations

Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Self-citation
Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 821
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
WAJCHENBERG, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 722
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 628
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 587
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell-Jones, D. L., & Khan, R. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 569
The incretin system and its role in type 2 diabetes mellitus
Holst, J. J., Vilsboll, T., & Deacon, C. F. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 528
Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J. P., Verhoeven, R., Bugáňová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 467
Self-citation
GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress
Yusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 454
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Gilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407
One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Olive (Olea europaea L.) Leaf Polyphenols Improve Insulin Sensitivity in Middle-Aged Overweight Men: A Randomized, Placebo-Controlled, Crossover Trial
de Bock, M. I., Derraik, J. G. B., Brennan, C. M., Biggs, J. B., Morgan, P. E., Hodgkinson, S. C., Hofman, P. L., & Cutfield, W. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057622 · Cited by 306
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
Nauck, M. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 298
Therapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288
“Liraglutide and semaglutide are administered at different frequencies and doses, and over a 24-hour period, they have distinct pharmacodynamic effects (37,38).”
Background
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Åhrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 276
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Exenatide (Exendin-4) Improves Insulin Sensitivity and β-Cell Mass in Insulin-Resistant Obesefa/faZucker Rats Independent of Glycemia and Body Weight
Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A., Parkes, D. G., & Young, A. A. (2004) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 241
Small-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232
Self-citation
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide
Jacobsen, L. V., Hindsberger, C., Robson, R. A., & Zdravkovic, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03536.x · Cited by 216
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Self-citation
Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not
Raun, K., von Voss, P., Gotfredsen, C. F., Golozoubova, V., Rolin, B., & Knudsen, L. B. (2006) · Diabetes · doi:10.2337/db06-0565 · Cited by 207
A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE -/- mouse model
Gaspari, T. A., Liu, H., Welungoda, I., Hu, Y., Widdop, R. E., Knudsen, L. B., Simpson, R. W., & Dear, A. E. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404257 · Cited by 203
The glucagonoma syndrome and necrolytic migratory erythema: a clinical review
van Beek, A., de Haas, E., van Vloten, W., Lips, C., Roijers, J., & Canninga-van Dijk, M. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510531 · Cited by 202
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
Matthews, J. E., Stewart, M. W., Boever, E. H. D., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M., & for the Albiglutide Study Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1518 · Cited by 198
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198
Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
Liu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0468 · Cited by 187
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179
Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism
Liu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 177
Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight
Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Bjerre Knudsen, L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 155
Differences in the HbA1c ‐lowering efficacy of glucagon‐like peptide‐1 analogues between Asians and non‐Asians: a systematic review and meta‐analysis
Kim, Y. G., Hahn, S., Oh, T. J., Park, K. S., & Cho, Y. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12293 · Cited by 172
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro
Bregenholt, S., Møldrup, A., Blume, N., Karlsen, A. E., Friedrichsen, B. N., Tornhave, D., Knudsen, L. B., & Petersen, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.013 · Cited by 168
Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment
Wang, L., Li, P., Tang, Z., Yan, X., & Feng, B. (2016) · Scientific Reports · doi:10.1038/srep33251 · Cited by 165
Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis: Incretins, gastric emptying and metabolic control
Edholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164
Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study
Beysen, C., Murphy, E. J., Deines, K., Chan, M., Tsang, E., Glass, A., Turner, S., Protasio, J., Riiff, T. J., & Hellerstein, M. K. (2011) · Diabetologia · doi:10.1007/s00125-011-2382-3 · Cited by 164
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Glucagon-like peptide-1, glucose homeostasis and diabetes
Holst, J. J., Deacon, C. F., Vilsbøll, T., Krarup, T., & Madsbad, S. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.01.003 · Cited by 162
Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis
Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S. (2007) · Diabetes · doi:10.2337/db06-1182 · Cited by 158
Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice
Waget, A., Cabou, C., Masseboeuf, M., Cattan, P., Armanet, M., Karaca, M., Castel, J., Garret, C., Payros, G., Maida, A., et al. (2011) · Endocrinology · doi:10.1210/en.2011-0286 · Cited by 153
Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes
Feinglos, M. N., Saad, M. F., Pi-Sunyer, F. X., An, B., Santiago, O. M., & on behalf of the Liraglutide Dose‐Response Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01567.x · Cited by 148
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
Lorenz, M., Pfeiffer, C., Steinstraesser, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 147
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 149
Liraglutide: A New Option for the Treatment of Obesity
Nuffer, W. A., & Trujillo, J. M. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1639 · Cited by 148
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
Neumiller, J. J. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09078 · Cited by 144
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial
Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study
Bonadonna, R. C., Heise, T., Arbet‐Engels, C., Kapitza, C., Avogaro, A., Grimsby, J., Zhi, J., Grippo, J. F., & Balena, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1041 · Cited by 142
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
Russell-Jones, D. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.018 · Cited by 137
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
Madsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 129
Glucagon and Type 2 Diabetes: the Return of the Alpha Cell
Lund, A., Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0555-4 · Cited by 127
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
Holst, J. J., & Deacon, C. F. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.005 · Cited by 120
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
Seino, Y., Rasmussen, M. F., Zdravkovic, M., & Kaku, K. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.03.018 · Cited by 117
Diabesity: therapeutic options
Colagiuri, S. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01182.x · Cited by 121
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 120
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus
Montanya, E., & Sesti, G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.034 · Cited by 120
Expansion of the Homeostasis Model Assessment of β-Cell Function and Insulin Resistance to Enable Clinical Trial Outcome Modeling Through the Interactive Adjustment of Physiology and Treatment Effects: iHOMA2
Hill, N., Levy, J., & Matthews, D. (2013) · Diabetes Care · doi:10.2337/dc12-0607 · Cited by 123
The effects of glucagon‐like peptide‐1 on the beta cell
Vilsbøll, T. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01073.x · Cited by 116
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D. G., & Diamant, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 114
Incretin hormone mimetics and analogues in diabetes therapeutics
Green, B. D., & Flatt, P. R. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.003 · Cited by 115
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. P. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 112
Glucagon‐like peptide agonists: A prospective review
Mariam, Z., & Niazi, S. K. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.462 · Cited by 121
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., PETERSON, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 110
Diabetes and Metabolism
Kowaltowski, A. J., & Abdulkader, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50968-2_9 · Cited by 106
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Ma, H., Lin, Y., Dai, L.-Z., Lin, C., Huang, Y., & Liu, S.-Y. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-061807 · Cited by 125
Glucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential
Gromada, J., Brock, B., Schmitz, O., & Rorsman, P. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.t01-1-pto950502.x · Cited by 103
Self-citation
Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes
Pacini, G., Mari, A., Fouqueray, P., Bolze, S., & Roden, M. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12452 · Cited by 103
Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management
Hiramoto, B. A., McCarty, T. R., Lodhia, N. A., Jenkins, A., Elnaiem, A. D., Muftah, M., Flanagan, R. F., & Chan, W. W. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002820 · Cited by 109
Incretin physiology beyond glucagon‐like peptide 1 and glucose‐dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides
Rehfeld, J. F. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02235.x · Cited by 99
The role of glucagon on type 2 diabetes at a glance
Godoy‐Matos, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-91 · Cited by 103
Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes
Hui, H., Zhao, X., & Perfetti, R. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.553 · Cited by 99
Allosteric ligands for G protein-coupled receptors: A novel strategy with attractive therapeutic opportunities
Amici, M. D., Dallanoce, C., Holzgrabe, U., Tränkle, C., & Mohr, K. (2009) · Medicinal Research Reviews · doi:10.1002/med.20166 · Cited by 97
GLP ‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
Trujillo, J. M., & Nuffer, W. A. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1507 · Cited by 97
GLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 99
Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
Vilsbøll, T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.231 · Cited by 95
Liraglutide, a Once‐daily Human Glucagon‐like Peptide‐1 Analog, Minimizes Food Intake in Severely Obese Minipigs
Raun, K., von Voss, P., & Knudsen, L. B. (2007) · Obesity · doi:10.1038/oby.2007.204 · Cited by 93
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes
Nielsen, L. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03460-4 · Cited by 93

Authors: Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O.
Affiliations: Aarhus University (DK)
Novo Nordisk (Denmark) (DK)
Case Western Reserve University (US)
ORCID: Degn, Kristine B.
Juhl, Claus B.
Sturis, Jeppe
Brock, Birgitte
Venue: Diabetes
Publisher: American Diabetes Association
Published: 2004-05-01
Volume: 53
Issue: 5
Pages: 1187-1194
ISSN: 0012-1797 (ISSN-L)
1939-327X
DOI: 10.2337/diabetes.53.5.1187
OpenAlex: W2102400698
Cited by: 427
References: 50
Citations by year: 2026: 3 · 2025: 5 · 2024: 9 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 10 · 2019: 6 · 2018: 13 · 2017: 7 · 2016: 27 · 2015: 24 · 2014: 27 · 2013: 30 · 2012: 21
FWCI: 16.53
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes (publishedVersion)
PubMed (publishedVersion)
Funders: Novo Nordisk
Diabetesforeningen
National Institutes of Health
U.S. Public Health Service (NIH 14507)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: liraglutide, glucagon-like peptide-1, type 2 diabetes, gluconeogenesis, glycogenolysis, insulin secretion, first-phase insulin response, proinsulin/insulin ratio, glucagon, gastric emptying, free fatty acids, disposition index, arginine stimulation test, hyperglycemic clamp
MeSH terms: Liraglutide, Circadian Rhythm, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Gastric Emptying, Glucagon, Glucose, Hormones, Humans, Hypoglycemic Agents, Insulin Resistance, Islets of Langerhans, Male, Middle Aged, Cross-Over Studies, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks